Old Web
English
Sign In
Acemap
>
Paper
>
ATIM-23. PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM
ATIM-23. PHASE I TRIAL OF ANTI-LAG-3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM
2017
Michael Lim
Xiaobu Ye
Burt Nabors
Anna Piotrowski
Joy D. Fisher
Serena Desideri
Megan Sims
Patrick Y. Wen
Stuart A. Grossman
Keywords:
Immunology
Lag
CD137
Medicine
in patient
Internal medicine
Oncology
anti pd 1
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]